MedPath
HSA Approval

PARECOXIB-AFT POWDER FOR SOLUTION FOR INJECTION 40MG

SIN17012P

PARECOXIB-AFT POWDER FOR SOLUTION FOR INJECTION 40MG

PARECOXIB-AFT POWDER FOR SOLUTION FOR INJECTION 40MG

May 17, 2024

APEX PHARMA MARKETING PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantAPEX PHARMA MARKETING PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION

INTRAVENOUS, INTRAMUSCULAR

Medical Information

M01AH04

Manufacturer Information

APEX PHARMA MARKETING PTE. LTD.

QILU PHARMACEUTICAL (HAINAN) CO., LTD.

Active Ingredients

Parecoxib Sodium eqv Parecoxib

40mg

Parecoxib

Documents

Package Inserts

Parecoxib-AFT Powder for Solution for Injection PI.pdf

Approved: May 17, 2024

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

PARECOXIB-AFT POWDER FOR SOLUTION FOR INJECTION 40MG - HSA Approval | MedPath